The Parexel Podcast | Episode 13: The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19
Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Chief Operating and Growth Officer, talks with Paul Bridges, Head of Consulting, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism. After listening, you can read more about Paul and Sheela’s perspective in this article: https://regulatory-access.parexel.com/parexels-covid-19-expert-content/covid-19-and-the-new-pragmatism
Related Insights
Whitepaper
Master Protocols from Design to Delivery
Sep 30, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
What COVID Taught Us About Focus, Innovation, and Leadership
Sep 24, 2021
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Related Insights
Whitepaper
Master Protocols from Design to Delivery
Sep 30, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
What COVID Taught Us About Focus, Innovation, and Leadership
Sep 24, 2021
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023